Response to: “Is Gauchian genotyping of GBA1 variants reliable?”
By Emma Sherrell onPreprint: To understand the cause of these discrepancies, the team reviewed their data, and concluded that they are misinterpreting Gauchian results in 8 of the 11 discrepant samples, and incorrectly using Gauchian to analyze low-coverage 1kGP samples.
Population fraction of Parkinson’s disease attributable to preventable risk factors
By Emma Sherrell onThe complete R-based Posit project reproduces the analyses and output in the article, "Population fraction of Parkinson's disease attributable to preventable risk factors."
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
By Emma Sherrell onThe code provided here is the same "Supplementary Code" that is provided in the supplement of the manuscript. Individual level raw shotgun sequences and metadata are available on NCBI Sequence Read Archive (SRA) under BioProject ID PRJNA834801.
Characterizing dysbiosis of the Parkinson’s disease gut microbiome using shotgun metagenomics
By Emma Sherrell onTo characterize the dysbiosis at species, gene family, and metabolic pathway resolution, the authors enrolled 490 PD and 234 age and geographically matched neurologically healthy individuals, collected stool and metadata, and conducted deep shotgun metagenomic sequencing of fecal DNA. Sequences and metadata are provided here.
Microbial amyloids in neurodegenerative amyloid diseases
By Emma Sherrell onPublished: Inhibiting microbial amyloids or their interactions with the host, may therefore represent a tangible target to limit various amyloid pathologies.
Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
By Emma Sherrell onThese results highlight a potential link for further exploration between nanoplastic pollution and α-synuclein aggregation associated with Parkinson’s disease and related dementias.
A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis
By Emma Sherrell onPreprint: The team provides a comprehensive evaluation of multiple systems in a prevalent experimental model of intestinal permeability, which will inform future studies using this model and others, assist in the identification of druggable targets in the gut-brain axis, and contribute to our understanding of the concomitance of intestinal and neuropsychiatric dysfunction.
The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner
By Emma Sherrell onPreprint: LRRK2 has become an appealing target in PD, but findings suggest that more research is required to understand the cell-type-specific consequences and optimal timing of LRRK2-targeting therapeutics.
Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors
By Emma Sherrell onGraphical abstract.
CryoEM structures of amplified alpha-synuclein fibril class A type I with extended core from DLB case I
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli BL21(DE3) Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class A type I with compact core from DLB case III
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B type II with extended core from DLB case I
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli BL21(DE3) Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case II
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B type I with compact core from DLB case III
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type II with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case X
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
Alpha-synuclein fibril from spontaneous control
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No